This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Reasons to Retain Revvity (RVTY) Stock in Your Portfolio Now
by Zacks Equity Research
Revvity's (RVTY) strong product portfolio raises optimism about the stock.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Avantor (AVTR) Launches Solutions for Gene Therapy Harvest
by Zacks Equity Research
Avantor's (AVTR) solutions are intended to provide gene therapy manufacturers with sustainable and efficient alternatives to traditional methods, thus improving viral particle harvest and quality
Masimo's (MASI) WI Sport Wearable Gets a New Powerful Feature
by Zacks Equity Research
Masimo (MASI) announces Sleep Halo, a new feature for its Masimo W1 Sport advanced health tracking wearable.
GE Healthcare (GEHC) Enters Partnership to Boost MRI Technology
by Zacks Equity Research
GE Healthcare's (GEHC) alliance is likely to establish an Innovative MRI Research and Development center to advance MRI innovation and patient care
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
by Zacks Equity Research
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.
PacBio (PACB) and Form Bio to Boost AAV Industry Development
by Zacks Equity Research
PacBio (PACB) and Form Bio collaborate to form an expert AAV Working Group to introduce essential tools for AAV development and research professionals.
Zacks Value Trader Highlights: BASF, Ford Motor, KB Home, PVH and Universal Health Services
by Zacks Equity Research
BASF, Ford Motor, KB Home, PVH and Universal Health Services are part of the Zacks Value Trader blog.
5 Top Ranked Classic Value Stocks for June 2024
by Tracey Ryniec
With major indexes hitting new all-time highs, are there any classic value stocks left?
Masimo (MASI), Cleveland Clinic Unite to Enhance Patient Care
by Zacks Equity Research
Masimo (MASI) collaborates with Cleveland Clinic to boost patient care by combining its Hospital Automation platform with the latter's central patient monitoring platforms.
Community Health (CYH) & Cost Plus Drugs Expand Collaboration
by Zacks Equity Research
Community Health (CYH) is now set to source drugs from the Cost Plus Drugs Marketplace under the new expanded partnership.
Zacks.com featured highlights The Gap, Universal Health Services and Inter
by Zacks Equity Research
The Gap, Universal Health Services and Inter have been highlighted in this Screen of The Week article.
Zacks Investment Ideas feature highlights: Tenet Healthcare and United Health Services
by Zacks Equity Research
Tenet Healthcare and United Health Services have been highlighted in this Investment Ideas article.
Top Health Care Stocks Beating the S&P 500 This Year
by Bryan Hayes
The health care space contains several market leaders that are widely outperforming.
BD's (BDX) New Research Tool to Aid Single-Cell Analysis
by Zacks Equity Research
BD (BDX) announces the commercial launch of its new single-cell research tool, BD Rhapsody ATAC-Seq Assay, to help researchers understand DNA regulation.
3 Stocks With Upgraded Broker Ratings to Buy for Robust Returns
by Swayta Shah
Brokers have deeper insights into stocks and macroeconomic factors. So, one should follow broker rating upgrades to pick stocks like Gap Inc. (GPS), Universal Health (UHS) and Inter & Co (INTR).
Ekso Bionics' (EKSO) New Partnership to Aid Its Ekso Devices
by Zacks Equity Research
Ekso Bionics (EKSO) announces a research partnership with Shepherd Center to create training and research programs for the Ekso devices.
Here's Why You Should Retain HealthEquity (HQY) Stock for Now
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Despite Fast-paced Momentum, Universal Health Services (UHS) Is Still a Bargain Stock
by Zacks Equity Research
Universal Health Services (UHS) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection
by Zacks Equity Research
AxoGen (AXGN) announces the full launch of its Avive+ Soft Tissue Matrix to provide comprehensive solutions for nerve protection.
Here's Why You Should Add Ecolab (ECL) to Your Portfolio Now
by Zacks Equity Research
Ecolab's (ECL) focus on research and development raises optimism about the stock
Universal Health Services (UHS) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Universal Health Services (UHS) could produce exceptional returns because of its solid growth attributes.
Are Investors Undervaluing Universal Health Services (UHS) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Universal Health Services, Inc. (UHS) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Universal Health Services (UHS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.